Neurology · Wisconsin
Neurology studies in Wisconsin
39 studies have at least one recruiting site in Wisconsin. Neurology research spans migraine, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke and nerve pain.
39 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1
The Gut - PRO Study
University of Wisconsin, Madison
- Location
- Madison, WI
- Eligibility basics
- Ages 60+
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Milwaukee, WI + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor
AbbVie
- Location
- Greenfield, WI + 17 other US sites
- Eligibility basics
- Ages 18–85
- RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC
- Location
- Milwaukee, WI + 18 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Milwaukee, WI + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S
- Location
- Milwaukee, WI + 13 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A/S
- Location
- Milwaukee, WI + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Milwaukee, WI + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Milwaukee, WI + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Milwaukee, WI + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Milwaukee, WI + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development, LLC
- Location
- Milwaukee, WI + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Kenosha, WI + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Madison, WI + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Madison, WI + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Milwaukee, WI + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Bristol-Myers Squibb
- Location
- Milwaukee, WI + 4 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
- Location
- Milwaukee, WI + 7 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
SetPoint Medical Corporation
- Location
- Milwaukee, WI + 8 other US sites
- Eligibility basics
- Ages 22–60
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Greenfield, WI + 42 other US sites
- Eligibility basics
- Ages 40–70
- RecruitingPhase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
AstraZeneca
- Location
- Milwaukee, WI + 4 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 1/Phase 2
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V.
- Location
- Milwaukee, WI + 15 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 1/Phase 2
A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations
Regeneron Pharmaceuticals
- Location
- Milwaukee, WI + 8 other US sites
- Eligibility basics
- Any age listed
- Recruiting
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
W.L.Gore & Associates
- Location
- Milwaukee, WI + 30 other US sites
- Eligibility basics
- Ages 18–70
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Why do memory studies need a study partner?
A partner can report day-to-day changes the participant may not notice. Each study explains what the partner is asked to do.